Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review. by Besada, Emilio
© 2014 Besada. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Patient Preference and Adherence 2014:8 1051–1059
Patient Preference and Adherence Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1051
R e v i e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/PPA.S34958
Potential patient benefit of a subcutaneous 
formulation of tocilizumab for the treatment  
of rheumatoid arthritis: a critical review
emilio Besada
Bone and Joint Research Group, 
Department of Clinical Medicine, 
Faculty of Health Sciences, UiT 
the Arctic University of Norway, 
Tromsø, Norway
Correspondence: emilio Besada 
Bone and Joint Research Group, institute 
of Clinical Medicine, University of Tromsø, 
9037 Tromsø, Norway 
Tel +47 7762 7294  
Fax +47 7762 7258  
email emilio.besada@uit.no 
Abstract: Treatment of rheumatoid arthritis (RA) was revolutionized during the last decade 
with the development of new biologic disease-modifying anti-rheumatic drugs (DMARDs) 
enabling the targeting of immune cells and cytokines other than tumor necrosis factor (TNF). 
Subcutaneous formulations of the newer biologic DMARDs facilitate not only patients’ 
emancipation from the hospital, but reduce both societal and medical costs. Intravenous tocili-
zumab (TCZ) in RA has an efficacy and safety profile similar to anti-TNF in both the short 
and long-term. However, TCZ can be administered in monotherapy without loss of efficacy 
when patients do not tolerate methotrexate or synthetic DMARDs. TCZ is consistently found 
superior to methotrexate and possibly superior to adalimumab in monotherapy in randomized 
controlled trials. Subcutaneous administration of TCZ is as effective and safe as its intravenous 
administration in RA patients during the first year of treatment. Similar to intravenous TCZ, 
patients’ weight and possibly previous use of anti-TNF influence the efficacy of subcutane-
ous TCZ. Additionally, combination with synthetic DMARDs seems to expose RA patients 
to more adverse events independently of its administration route. Pharmacokinetics of dif-
ferent administration routes could potentially lead to differences in efficacy, adverse events, 
and auto-immunogenicity. The concentration of free TCZ before new TCZ dose (C trough) is 
higher in the subcutaneous route, while the maximal concentration of free TCZ is higher in the 
intravenous route. The subcutaneous dosages of TCZ 162 mg every week, and every 2 weeks 
in RA patients with low body weight (60 kg) work well. Nevertheless, dosage and intervals 
of subcutaneous TCZ administration could be adjusted during the course of treatment since 
80% of non-Japanese RA patients with usually higher body weight achieved similar efficacy 
with the low TCZ dosage in combination with a synthetic DMARD. Patients want effective, 
easy-to-administer therapy with sustained prolonged efficacy without the need of polypharmacy 
and with minimal to no side effects. Subcutaneous TCZ in RA patients in monotherapy seems 
to live up to patients’ expectations.
Keywords: tocilizumab, subcutaneous, rheumatoid arthritis, pharmacokinetic, safety, 
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Introduction
Rheumatoid arthritis (RA) is a chronic systemic inflammatory auto-immune disease 
responsible for articular and extra-articular affection. Clinical features of RA include 
symmetric polyarthritis of small joints and morning stiffness.1 More than a third of 
RA patients eventually experience work disability2 and life expectancy is shortened 
by 3–5 years due to disease and treatment-related adverse effects.3
Major advances in the management of RA are early diagnosis4 and prompt aggres-
sive treatment aiming at remission.5 European League Against Rheumatism (EULAR) 
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recommendations6 and treatment algorithms serving as 
pragmatic approaches in the management of RA1 have been 
published and have become standard-of-care.
Glucocorticoids, synthetic disease-modifying antirheu-
matic drugs (DMARD) and in the last 20 years biologic 
DMARD are used to treat RA. A combination of synthetic 
DMARD – especially methotrexate (MTX) – and biologic 
DMARD (anti-tumor necrosis factor (TNF), abatacept, 
rituximab, and tocilizumab [TCZ]) is recommended 
in patients responding inadequately to MTX after 3–6 
months.6 Previous preference for a combination of anti-
TNF and MTX is no longer suggested in the last EULAR 
recommendations since abatacept and TCZ are as effective 
and safe as anti-TNF.6
Interleukin-6 (IL-6) is a pleiotropic cytokine involved in 
inflammation and infection responses, but also in the regula-
tion of metabolic, regenerative, and neural processes.7 IL-6 
targets cells with membrane bound IL-6 receptors (classic 
signaling), but also all other cells since IL-6 binds to the sol-
uble form of IL-6 receptor which interacts with the signaling 
receptor protein gp130 (trans-signaling).7 Pro-inflammatory 
responses of Il-6 are rather mediated by trans-signaling.7 
In RA patients, levels of IL-6 are increased in the synovial 
fluid and tissue and correlate with C-reactive protein (CRP) 
and disease activity.8
TCZ is a recombinant humanized anti-IL-6 receptor 
monoclonal antibody approved in RA (intravenously at 
the dose of 4–8 mg/kg every 4 weeks [q4w]) and in juve-
nile idiopathic arthritis (from 8–12 mg/kg every 2 weeks 
[q2w]) in Europe and the US.9 TCZ has also been used in 
Castleman disease and in non-RA systemic inflammatory 
rheumatic diseases such as adult-onset Still’s disease, giant 
cell arteritis, Takayasu arteritis, polymyalgia rheumatica, 
relapsing polychondritis, systemic lupus erythematosus, and 
systemic sclerosis.9
Subcutaneous formulations of biologic DMARD other 
than anti-TNF, such as abatacept10 and TCZ in RA, have been 
developed in order to facilitate their use outside hospitals by per-
mitting self-administration. The use of subcutaneous biologic 
agents other than anti-TNF could also be attractive in patients 
with non-RA systemic inflammatory rheumatic diseases.
A systematic search of the literature conducted prior to 
March 2014 with PubMed of the US National Library of 
Medicine and Google scholar using the key terms tocilizumab 
and subcutaneous identified two phase I/II and three phase III 
studies of subcutaneous TCZ in RA patients.11–16 The objec-
tive of the review is to present the available data concerning 
the pharmacokinetics, efficacy, and safety of subcutaneous 
TCZ in RA patients.
Main differences between studies
BREVACTA and SUMMACTA were global studies and 
comprised patients with RA from North and South America, 
Europe, and Asia (other than Japan),13–15 whereas MAT-
SURI and MUSASHI only comprised Japanese patients 
(see Table 1).12,16 
MATSURI was a phase I/II study that aimed to deter-
mine the appropriate dose of TCZ in Japanese RA patients,12 
whereas the three other studies were phase III studies that 
aimed to establish the efficacy of subcutaneous TCZ for-
mulation against placebo13,14 and against intravenous TCZ 
administration.15,16 The primary outcome of the two stud-
ies comparing subcutaneous and intravenous TCZ was to 
demonstrate the non-inferiority of subcutaneous TCZ when 
compared to intravenous TCZ with regard to efficacy.15,16 
The non-inferiority margins used in the SUMMACTA and 
MUSASHI studies, 12% and 18% respectively, were defined 
empirically.15,16 The choice of the non-inferiority margin 
in the MUSASHI study was determined as a third of the 
 difference of American College of Rheumatology (ACR) 
Table 1 Characteristics of studies of subcutaneous tocilizumab in rheumatoid arthritis patients 
Phase Type of study Number  
of patients 









Open trial 8, 12, 12 81 mg q2w SC 
162 mg q2w SC 
162 mg qw SC





iii db RCT 437 vs 219 TCZ 162 mg q2w SC vs 
placebo 




iii db, dd Non-inferiority 
RCT
558 vs 537 TCZ 162 mg qw SC vs 
TCZ 8 mg/kg q4w iv




iii db, dd Non-inferiority 
RCT
159 vs 156 TCZ 162 mg q2w SC vs 
TCZ 8 mg/kg q4w iv
None ACR20 24 w NA
Abbreviations: ACR, American College of Rheumatology response rate 20; db, double-blind; dd, double dummy; DMARD, disease-modifying antirheumatic drugs; iv, intravenous; 
NA, not available; qw, every week; q2w, every two weeks; q4w, every 4 weeks; RCT, randomized controlled study; SC, subcutaneous; TCZ, tocilizumab; vs, versus; w, weeks.




SC tocilizumab in RA
20 response ($20% improvement in swollen joint count 
and in tender joint count plus $20% improvement in three 
of the following domains: Patient pain, patient global disease 
activity, physician global disease activity, physical function 
and acute-phase reactants ESR or CRP) between TCZ and 
placebo from the SATORI study.17
All patients included in these studies had an inadequate 
response to both synthetic and biologic DMARD therapy: 20% 
had failed anti-TNF treatment prior to receiving TCZ.13–16 
Patients’ inclusion criteria were six or more swollen joints 
(66-joint count) and eight of more tender joints (68-joint 
counts) in the BREVACTA and MUSASHI studies,13,14,16 
while the SUMMACTA study included patients with four 
or more swollen joints and four or more tender joints.15 
Even though the criteria were stricter in the SUMMACTA 
study, the means of the swollen joint count (SJC), the ten-
der joint count (TJC), and DAS28 (disease activity score) 
were equivalent in both the SUMMACTA and MUSASHI 
studies,15,16 suggesting greater variability in the SJC and TJC 
in the SUMMACTA study.15 CRP and erythrocyte sedimenta-
tion rate (ESR) were also inclusion criteria that were equal 
between studies: CRP was 10 mg/L or higher and ESR was 
28–30 mm/h or higher.15,16
The three phase III studies permitted RA patients to 
continue their oral glucocorticoids (10 mg/day predniso-
lone or equivalent) and oral non-steroidal anti-inflammatory 
drugs during the course of the study.13–16 Nevertheless, the 
TCZ dosage and the use of concomitant DMARD was dif-
ferent in these three studies. The BREVACTA and SUM-
MACTA studies included patients receiving subcutaneous 
TCZ in combination with a stable dose of DMARD.13,14,16 
In the SUMMACTA study patients received TCZ 162 mg 
weekly,16 while patients in the BREVACTA study received 
TCZ 162 mg q2w.13,14 In the BREVACTA study, 11% of 
the patients increased TCZ to a weekly dose since they had 
less than 20% improvement in their SJC and TJC between 
week 12 and 48.14 In the MUSASHI study, patients received 
TCZ 162 mg q2w in monotherapy without any washout 
periods for synthetic DMARDs.16
Baseline characteristics of RA patients were not available 
in the BREVACTA study, but were available in the other 
studies. RA patients were comparable in terms of sex dis-
tribution, age, disease duration, disease activity (TJC, SJC, 
DAS28), physician’s global assessment of disease activity, 
rheumatoid factor positivity, and CRP levels at baseline.15,16 
Non-Japanese RA patients were heavier than Japanese: 
means of 74 versus (vs) 54 kg.15,16 Japanese patients had lower 
pain scores and lower global assessment of disease activity 
than non-Japanese,15,16 possibly reflecting cultural differences 
between the enrolled patients. RA patients in the MUSASHI 
studies were more often anti-citrullinated protein antibody 
(ACPA) positive – 90% vs 73% – and used daily oral glu-
cocorticoids more often 69%–59% vs 54%.15,16 Of interest, 
patients in the subcutaneous treatment arm were treated more 
frequently with glucocorticoids than the intravenous arm in 
the MUSASHI study.16
TCZ pharmacokinetics
(See Table 2). A previous phase II study in RA patients 
receiving intravenous TCZ 8 mg/kg q2w determined that 
a concentration of free TCZ above 1 μg/mL in the serum 
enables the binding of 95% of the soluble IL-6 receptor 
inhibiting IL-6 actions and doubling the IL-6 serum levels 
after 2 weeks.11 Serum concentration of free TCZ above 1 μg/
mL also normalized CRP in RA patients.11 
In all the studies, RA patients receiving TCZ either 
162 mg weekly or q2w achieved a serum concentration of 
pre-dose TCZ (C trough) largely above 1 μg/mL.12–16 
Table 2 Pharmacokinetics of different subcutaneous tocilizumab dosages compared to intravenous tocilizumab in rheumatoid arthritis 
patients
TCZ dose C max  
μg/mL 
1 dose
C max μg/mL 







C trough  
μg/mL
MATSURi12 81 mg q2w SC 
162 mg q2w SC 















25–30 at 15 w 
BRevACTA13 162 mg q2w SC + DMARD 10 17 at week 12 4,088 during weeks 12 to 14 20 7.4 at 24 w
SUMMACTA15 162 mg qw SC vs 8 mg/kg q4w  
iv + DMARD
NA 53 vs 233 
at week 20
30,168 vs 41,304 during weeks  
20 to 24 
12 42 vs 18 at 24 w
MUSASHi16 162 mg q2w SC vs 8 mg/kg q4w  
iv monotherapy
NA NA NA 12 11 vs 12 at 24 w 
Abbreviations: AUC, area under the curve; C max, maximal serum concentration of tocilizumab; C trough, pre-dose tocilizumab serum concentration; DMARD, disease-
modifying antirheumatic drugs; iv, intravenous; NA, not available; qw, every week; q2w, every two weeks; q4w, every 4 weeks; SC, subcutaneous; TCZ, tocilizumab; 
vs, versus; w, weeks.





Japanese patients receiving subcutaneous TCZ 162 mg 
q2w and intravenous TCZ 8 mg/kg q4w had similar 
pharmacokinetics.12,16 However, when subcutaneous TCZ 
162 mg was administered weekly in non-Japanese patients, 
the C trough level was two times higher than the C trough 
level of intravenous TCZ.15 On the other hand, RA patients 
receiving intravenous TCZ had higher maximal serum con-
centrations of free TCZ (C max) and a higher area under 
the curve.15
While the steady state of free TCZ concentration 
was achieved at week 12 in both the SUMMACTA and 
MUSASHI studies using two different subcutaneous TCZ 
dosages,15,16 time to steady state seemed dependent on the 
TCZ dosage and the weight of RA patients. Administration 
of intravenous TCZ 8 mg/kg q2w led to a steady state at 
6 weeks11 while it took 12 weeks when intravenous TCZ 
8 mg/kg was administered q4w.15,16 While using the same 
subcutaneous dose of TCZ, the steady state was attained 
later in non-Japanese RA patients than in Japanese,13,14,16 
possibly due to weight differences between patients.13,14 The 
time to steady state became equivalent between Japanese 
and non-Japanese RA patients when subcutaneous TCZ 162 
mg was administered weekly in non-Japanese patients.15
Eighty to 91% of the RA patients receiving subcutane-
ous TCZ 162 mg q2w in the MUSASHI study had serum 
free TCZ concentrations above 1 μg/mL after 4 weeks16 
inhibiting the IL-6 actions and normalizing CRP. In the 
SUMMACTA study, CRP and ESR were slightly lower in 
RA patients receiving subcutaneous 162 mg weekly than in 
patients receiving intravenous TCZ 8 mg/kg q4w, possibly 
due to higher C trough with subcutaneous TCZ.15
TCZ efficacy
(See Table 3). Intravenous TCZ is effective in RA either in 
monotherapy or in combination with DMARD/MTX in both 
naïve patients and patients with an inadequate response to 
DMARD after 24 weeks.18,19 ACR20 response ranged from 
56%–80%, ACR50 response from 39%–64% and ACR70 
response from 16%–44%.19 Combination therapy of intrave-
nous TCZ and MTX was not superior to TCZ monotherapy 
in patients with an inadequate response to DMARD.19,20 
In the three phase III studies, subcutaneous TCZ used either 
in monotherapy or in combination with DMARD had similar 
ACR responses compared to the intravenous TCZ literature and 
were not statistically inferior to the intravenous TCZ arms.15,16 
DAS28 remission (DAS282.6), clinical disease activity 
index (CDAI) and Boolean remission index were equal in both 
the subcutaneous and the intravenous administration of TCZ 
either in monotherapy or in combination with DMARD.15,16
ACR responses were lower in RA patients with anti-
TNF failure with ACR20–50–70 responses of 50%, 28%, 
and 11%, respectively.19 In the ACT-SURE study (an 
open-label study close to clinical practice) RA patients 
with previous anti-TNF failure had lower DAS28 remission 
rates compared with anti-TNF naïve patients: 50% and 62%, 
respectively.21 However, in the MUSASHI study, prior use 
of anti-TNF did not influence the efficacy of the subcutane-
ous TCZ treatment arm, whereas body mass index (BMI) 
in the fourth quartile (from 23.4 to 29.6 kg/m2) decreased 
the ACR20–50–70 response rates significantly.16 Similarly, 
the ACR response rates of the heaviest category (weight 
$100 kg) in both the subcutaneous and intravenous TCZ 
arms were lower in the SUMMACTA study.15
Table 3 Efficacy of subcutaneous tocilizumab in rheumatoid arthritis patients with inadequate response to DMARD
TCZ dose Week ACR20% ACR50–70%* DAS282.6% CDAI2.8% Boolean % HAQ-DI$0.3% Insufficient 
response %
MATSURi12 81 mg q2w SC 
162 mg q2w SC 










































SUMMACTA15 162 mg qw SC 
+ DMARD
24 68 46–24 37 14 11 65 1.7
MUSASHi16 162 mg q2w SC  
monotherapy
24 79 64–37 50 16 16 57 1.7
SUMMACTA and 
MUSASHi studies15,16
8 mg/kg iv q4w

















Note: *The numbers listed first in this column refer to the percentage of the patients achieving the ACR50 response, and the numbers listed second in this column refer to 
the percentage of patients achieving the ACR70 response. By definition, all the patients achieving ACR70 achieve ACR50.
Abbreviations: ACR, American College of Rheumatology response rate; CDAi, clinical disease activity index; DAS, disease activity score; DMARD, disease-modifying 
antirheumatic drugs; HAQ-Di, health assessment questionnaire disability index; iv, intravenous; NA, not available; qw, every week; q2w, every two weeks; q4w, every four weeks; 
SC, subcutaneous; TCZ, tocilizumab.




SC tocilizumab in RA
ACR20–50–70 responses were significantly lower when 
TCZ was administered at half dose – 4 mg/kg q4w in combi-
nation with DMARD.19 Although there was no difference in 
efficacy between both TCZ intravenous dosages – 4 mg/kg 
vs 8 mg/kg in an open-label clinical practice study, 58% of 
the patients had dose escalation from 4–8 mg/kg during the 
course of the study.22 The efficacy of subcutaneous TCZ 
162 mg q2w in combination with DMARD seemed equal 
to TCZ 162 mg weekly,14,15 although 18% of the patients 
withdrew from BREVACTA and received escape therapy 
with weekly subcutaneous TCZ.14 Still, 80% of non-Japanese 
RA patients treated with TCZ 162 mg q2w in combination 
with DMARD achieved similar efficacy compared with TCZ 
administered weekly.14
Sustained efficacy of intravenous TCZ was demon-
strated in the STREAM study when 66% of the patients 
were still receiving intravenous TCZ 8 mg/kg q4w mono-
therapy after 5 years.23 In the STREAM study, TCZ was 
only stopped in 0.7% of the patients due to an insufficient 
response, although 5.6% withdrew due to personal rea-
sons.23 Sustained efficacy was also indirectly demonstrated 
in the DREAM study when at baseline 187 RA patients 
with previous inadequate response to DMARD had low 
disease activity (DAS283.2) after receiving a median of 
4 years of intravenous TCZ monotherapy.24 Intravenous 
TCZ had sustained efficacy in RA patients with prior 
DMARD and anti-TNF treatment failures (93%) since 
TCZ drug survival was 64% at 48 weeks and only 11% 
of the patients discontinued TCZ due to lack of efficacy 
in the Danish DANBIO registry.25 
Long-term efficacy of combining synthetic DMARD with 
subcutaneous TCZ was maintained over 48 weeks since less 
than 1% withdrew from the BREVACTA study.14 In the SUM-
MACTA and MUSASHI studies, only 1.7% had insufficient 
therapeutic response with subcutaneous TCZ, not different 
from the intravenous TCZ treatment arms at 24 weeks.15,16 
Intravenous TCZ either in monotherapy or in combination 
with MTX delayed radiographic progression at 52 weeks18 
independently of its effect on disease activity, similar to 
anti-TNF treatment.26 In the BREVACTA study, there was 
almost no radiographic progression of structural joint dam-
age from baseline and this remained unchanged from week 
24–48, changes using the modified total Sharp score were 
0.6±2.7 at 24 weeks and 0.6±3.3 at 48 weeks.14 
TCZ safety
(See Table 4). TCZ had sustained efficacy and high retention 
rates suggesting acceptable safety.19 Cumulative safety data 
from RA trials yielded a rate of adverse events (AE) of 278 
per 100 person-years (PY) and a rate of serious adverse events 
(SAE) of 14/100 PY.27 In the ACT-SURE and ACT-RAY 
studies, close to clinical practice, the rates of AE and SAE 
were significantly higher, 593 and 491/100 PY, and 20 and 
21/100 PY, respectively.20,21 In the ACT-STAR and STREAM 
studies, the overall rates of SAE were highest with 28/100 PY 
in both studies.22,23 While the most common SAE were 
infections,20,21 it was joint surgery in the long-term STREAM 
study, occurring in 14% of RA patients.23 Previous use of 
anti-TNF21,22 and concomitant use of synthetic DMARD20,22 
with intravenous TCZ did not increase SAE.
The rates of SAE in RA patients receiving subcutaneous 
TCZ were similar to the rates in intravenous TCZ RA trials,27 
but were lower when compared with studies close to clini-
cal practice.20–22 Rates of SAE were not different if patients 
received either 162 mg weekly or q2w and if patients received 
intravenous TCZ.14,15 The most common SAE in RA patients 
receiving subcutaneous TCZ were infections,14,15 similar to 
studies of equal duration.
Rates of severe infections (SI) ranged from 4.2–11.2 
infections per 100 PY.20–23 The most common infections were 
localized in the upper and lower airways.20,22,23 Cellulitis and 
herpes zoster infection came second respectively in the ACT-
STAR and STREAM studies.22,23 In the STREAM study, SI 
such as pneumonia, herpes zoster infection, acute bronchitis, 
and pyelonephritis were found in 6.3%, 4.9%, 1.4%, and 
1.4%, respectively, of the observed SAE with corresponding 
rates of 1.5, 1.1, 0.8, 0.5 events per 100 PY.23 Combination 
of intravenous TCZ 8 mg/kg with DMARD increased the 
risk of infections by 30% compared with controls receiving 
TCZ and placebo; however there was no difference between 
the two intravenous TCZ dosages – 4 and 8 mg/kg q4w.28 The 
incidence of infections and SI seemed lower in RA patients 
with less than 2 years of disease duration.19
Rates of SI in RA patients receiving subcutaneous 
TCZ seemed lower – 3.1 and 3.8 infections per 100 PY.14,15 
Although infections and SI frequency and rates were 
similar in both treatment arms, two patients had bacterial 
arthritis15 and two patients had herpes zoster infection16 in 
the intravenous TCZ arms, compared to none in the sub-
cutaneous TCZ treatment arms. No cases of tuberculosis 
were reported when using subcutaneous TCZ14–16 similar 
to intravenous TCZ.28
Mean neutrophil counts decreased during intravenous TCZ 
treatment in RA patients, but usually remained inside the normal 
range.23 Grade 2 and 3 neutropenia (neutrophil counts between 
1.0 to 1.5×109/L and between 0.5 to 1.0×109/L) occurred in 





7.0%–11% and 2.2%–6.1%, respectively.22,23 No patients 
had grade 4 neutropenia (neutrophil count 0.5×109/L).22,23 
In the ACT-STAR study, a proportion of RA patients with 
grade 2 and 3 neutropenia seemed higher in the treatment 
arm combining intravenous TCZ 8 mg/kg and DMARD 
compared to the TCZ monotherapy.22 TCZ seemed to cause 
neutropenia since the risk of grade 3 neutropenia was neg-
ligible in MTX monotherapy compared to intravenous TCZ 
monotherapy, 0.4% vs 3.1% respectively.29 Neutropenia was 
usually transient independently of its grade and returned to 
normal after discontinuation of TCZ.19
In RA patients receiving subcutaneous TCZ, the risk of 
neutropenia seemed similar to that of the intravenous TCZ 
arms.15,16 Of interest, one patient in the SUMMACTA study 
had grade 4 neutropenia.15 Neutropenia was responsible for 
neither febrile neutropenia nor infections in RA patients 
receiving TCZ,28 independent of its administration route.15
Alanine aminotransferase (ALT) increased during TCZ 
from 19–26 UI/L at 24 weeks.30 In the long-term study 
STREAM, ALT increased slightly, but remained within 
normal range at 5 years.23 ALT elevation was mostly transient 
occurring only once in 49% and more than once in 7.8% of 
the patients receiving intravenous TCZ 8 mg/kg in combi-
nation with DMARD.20 ALT elevation was less frequent in 
RA patients receiving intravenous TCZ monotherapy, 1.2% 
compared with 28% receiving combination.20 Because of 
its transient character, TCZ discontinuation secondary to 
grade 1 and 2 elevation of ALT (up to five times the upper 
normal level) was infrequent, around 2%.9 No liver injury 
and hepatitis secondary to TCZ have been reported, except 
for one case of histologic hepatocellular necrosis that did not 
lead to its discontinuation.19
The frequency of ALT elevation in patients receiving sub-
cutaneous TCZ was similar to intravenous TCZ. The combi-
nation of subcutaneous TCZ and DMARD seemed to increase 
the risk of ALT elevation compared with monotherapy.15,16 
Only one patient (0.2%) had sustained elevation of ALT and 
five patients (0.8%) discontinued TCZ due to ALT elevation 
in the SUMMACTA study.15
Total cholesterol levels increased in the first 6 weeks of 
TCZ treatment and stabilized afterwards.19 Total cholesterol 
increased from 93 mg/dL to 103 mg/dL at 24 weeks in the 
ACT-RAY study,20 whereas it increased from 185 at base-
line to 220 at 12 months and 214 mg/dL at 60 months in the 
long-term STREAM study.23 Use of lipid-lowering treatment 
with statins was different between studies, at baseline 1.4% 
of Japanese patients used statins in the STREAM study23 






























































































































































































































































































































































































































































































































































































































































































































































































SC tocilizumab in RA
in the ACT-STAR study.22 Nevertheless, during the course 
of TCZ, 35% and 32% of the patients in both studies used 
statins, although the studies’ duration was unequal (5 years vs 
24 weeks).22,23 Dyslipidemia induced by TCZ did not appear 
to increase the risk of serious cardiovascular disease.19
Fifteen and 24% of RA patients receiving subcutane-
ous TCZ increased their total cholesterol levels from less 
than 200 mg/dL to over 240 mg/dL respectively in the 
SUMMACTA and MUSASHI studies.15,16 Total cholesterol 
levels seemed to increase less in non-Japanese patients, 
however, only 47% of the non-Japanese patients had total 
cholesterol levels less than 200 mg/dL at baseline15 compared 
with 79% of the Japanese patients.16 Another possible expla-
nation could be that non-Japanese patients were more often 
treated with statins at baseline.15 The authors of the SUM-
MACTA study mentioned that clinically relevant shifts in 
low-density lipoprotein cholesterol, high-density lipoprotein 
cholesterol, and triglyceride levels were similar between the 
subcutaneous and intravenous treatment arms.15
Rates of intravenous TCZ withdrawal due to AE or SAE 
ranged from 2.9%–8.8% at 24 weeks,20–22 mostly due to 
infections.21 Combination of TCZ and synthetic DMARD 
did not seem to increase the risk of withdrawal due to AE 
and SAE.22 In the long-term STREAM study, 22% of the 
patients withdrew from TCZ due to SAE, however, TCZ 
was frequently interrupted – 163 interruptions for 8 weeks 
or more in 143 RA patients during 5 years.23
The rates of subcutaneous TCZ withdrawal were similar 
to intravenous, ranging from 1.7%–6.3%.14–16 Contrary to 
intravenous, subcutaneous TCZ monotherapy seemed to have 
lower withdrawal rates due to AE.14–16 
Anti-TCZ antibodies were not more frequently detected 
in patients receiving subcutaneous TCZ compared with 
intravenous TCZ when combined with DMARD.15 However, 
anti-TCZ antibodies were more frequent in patients receiving 
subcutaneous TCZ monotherapy.16 Due to the low number 
of patients with anti-TCZ antibodies and the short duration 
of the studies, the consequences of anti-TCZ antibodies – in 
terms of AE and loss of efficacy – remain unknown. 
Ten deaths (0.3%) were recorded during the ACT-SURE, 
ACT-STAR, and ACT-RAY studies20–22 while the number 
of deaths was not reported during the long-term STREAM 
study.23 Four deaths were due to sepsis.20–22 
Six deaths were recorded in the BREVACTA study14 
while none were recorded in the other two studies15,16 cor-
responding to 0.5% of all the RA patients treated with sub-
cutaneous TCZ. The causes of deaths were not reported in 
the BREVACTA study.14 
Summary: from the physician’s  
to the patients’ perspective
Subcutaneous TCZ seems to be as effective as intravenous 
TCZ in treating RA patients either in monotherapy or in 
combination with DMARD. Subcutaneous TCZ offers 
patients the additional option of self-administration, which 
is important for patients with chronic disease who usually 
prefer to be treated at home. Reducing the number of hospital 
visits due to intravenous treatment could decrease societal 
and medical costs.
While EULAR recommendations in RA stated that 
biologic DMARD should be commenced with MTX, they 
also acknowledged that TCZ is the only biologic DMARD 
that demonstrated superior effects compared to MTX and 
which has some evidence supporting its use in monotherapy.6 
Recently, intravenous TCZ monotherapy was found more 
effective than adalimumab in RA patients for whom MTX 
was deemed inappropriate30 and was more effective than 
abatacept after anti-TNF and rituximab failure.31 Even 
though physician surveys indicate that a DMARD was 
prescribed with a biologic agent in 80%–90% of the RA 
patients,32 biologic monotherapy is commonly used in clinical 
practice – at least 30% and up to 54%.29,33 Subcutaneous 
TCZ could conciliate both treatment efficacy and patients’ 
personal preferences.
Safety of subcutaneous TCZ seemed similar to intra-
venous TCZ in the short-term. No infections secondary to 
neutropenia, episodes of liver failure or increased risk of 
cardiovascular diseases were recorded in studies evaluating 
subcutaneous TCZ. The safety profile of intravenous TCZ 
compared to other biologic DMARD was similar in terms of 
SAE, SI, lymphoma, and congestive heart failure.34 The risks 
of infections28 and ALT elevation20 seemed to be increased 
in RA patients receiving intravenous TCZ (8 mg/kg q4w) in 
combination with DMARD compared with patients receiving 
TCZ monotherapy. However, higher C max concentrations 
in RA patients receiving intravenous TCZ and higher C 
trough concentrations in patients receiving subcutaneous 
TCZ could lead to differences in AE and possibly in efficacy. 
Subcutaneous TCZ is therefore well tolerated, especially 
when administered in monotherapy although its subcutane-
ous administration could theoretically expose patients to 
auto-immunogenicity.35
Since RA patients were observed during 24 and 48 weeks, 
long-term effects and safety of subcutaneous TCZ have not 
yet been assessed. Still, long-term efficacy and safety of 
intravenous TCZ seemed good when measured in  retention 





rate.19,23 Retention rate in RA patients who were non-
responders to anti-TNF was higher with biologic DMARD 
other than anti-TNF,36 and between TCZ and infliximab37 in 
two small cohort studies. 
Monotherapy with intravenous TCZ has prolonged 
efficacy after its discontinuation since 13% of RA 
patients, who had received TCZ for a median of 4 years, 
had low disease activity 52 weeks after discontinuation.24 
Re-treatment with TCZ was well tolerated and effective 
in RA patients who experienced loss of efficacy after TCZ 
discontinuation.38 
Although the subcutaneous dosages of TCZ 162 mg every 
week and q2w in RA patients with low body weight (60 kg) 
worked well, dosage and intervals of subcutaneous TCZ admin-
istration could be adjusted during the course of treatment. 
Simple and important issues relevant to patients’ prefer-
ence and adherence, such as the place of TCZ in RA treat-
ment algorithms as a first-line or second-line treatment, its 
dosage and treatment intervals especially during long-term 
remission, have not yet been assessed since these issues are 
often not prioritized. 
Patients want effective, easy-to-administer therapy with 
sustained prolonged efficacy without the need of polyphar-
macy and with minimal to no side effects. Subcutaneous 
TCZ in RA patients in monotherapy promises to live up to 
patients’ expectations.
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